EpiBiologics

EpiBiologics

Biotechnology Research

San Mateo, California 2,962 followers

Next Generation Protein Degradation

About us

EpiBiologics is building a next-generation protein degradation platform that targets membrane and extracellular proteins. EpiBiologics was founded in 2022 based on the pioneering work from academic founder Dr. Jim Wells of the University of California San Francisco (UCSF). The Company’s proprietary EpiTAC platform is a modular antibody-based system that enables the precise degradation of disease-driving membrane and extracellular proteins in a tissue-specific manner. Headquartered in San Mateo, EpiBiologics is backed by leading healthcare investors and aims to develop first-in-class and best-in-class targeted therapies across multiple therapeutic areas. For more information, please visit epibiologics.com and follow us on LinkedIn.

Website
https://www.epibiologics.com/
Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
San Mateo, California
Type
Privately Held

Locations

  • Primary

    1900 Alameda de Las Pulgas

    San Mateo, California 94402, US

    Get directions

Employees at EpiBiologics

Updates

Similar pages

Funding

EpiBiologics 2 total rounds

Last Round

Series A

US$ 23.0M

See more info on crunchbase